Log-in
Sign-up
Webcast
Clinical Trials
Webcast
Clinical Trials
Home
>
Clinical Trials
Molecules
전체
Edoxaban
Olmesartan
Prasugrel
Pravastatin
Mirogabalin
Ramosetron
Trastuzumab deruxtecan
Status
Select
Check All
Search
Recruiting
Completed
Not yet recruiting
Enrolling by invitation
Active, not recruiting
Suspended
Terminated
Withdrawn
Unknown status
Email
Saved trials
Completed
NCT01465828
Therapy With High Clopidogrel Dose or Prasugrel Standard Dose Reduces the Platelet Reactivity in Patients With Genotype Variation RESET GENE Trial
30
Enrollment(s)
2
Study location(s)
Interventional (Phase III)
Acute Coronary Syndrome
Unknown status
NCT01557075
Aspirin Mono Therapy 12-months After Drug-eluting Stents Implantation
2,000
Enrollment(s)
1
Study location(s)
Interventional (Phase IV)
Drug-eluting Stent (DES)
Completed
NCT00846365
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
1,085
Enrollment(s)
0
Study location(s)
Interventional (Phase III)
Essential Hypertension
Terminated
NCT01107899
Study to Learn When Platelets Return to Normal After One Loading Dose of Anti-platelet Drugs in Patients With Symptoms of Acute Coronary Syndromes
29
Enrollment(s)
1
Study location(s)
Interventional (Phase I)
Acute Coronary Syndromes
Completed
NCT01305369
The Effect of Prasugrel on Bronchial Hyperreactivity and on Markers of Inflammation in Patients With Chronic Asthma
26
Enrollment(s)
1
Study location(s)
Interventional (Phase IV)
Chronic Asthma
Unknown status
NCT01046461
Ramosetron, Aprepitant and Dexamethasone (RAD) in Solid Cancer
41
Enrollment(s)
1
Study location(s)
Interventional (Phase II)
Solid Tumour
Postoperative Nausea and Vomiting
Completed
NCT01178099
An Assessment of Prasugrel on Healthy Adults and Sickle Cell Adults
26
Enrollment(s)
1
Study location(s)
Interventional (Phase I)
Anemia, Sickle Cell
Completed
NCT01033071
Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hypertension.
1,071
Enrollment(s)
0
Study location(s)
Interventional (Phase III)
Essential Hypertension
91
92
93
94
95